Marksans Pharma Ltd
NSE:MARKSANS
Marksans Pharma Ltd
NSE:MARKSANS
Price:
156.89
INR
-3.8%
Market Cap:
₹71.1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Marksans Pharma Ltd
NSE:MARKSANS
|
IN |
|
Delorean Corporation Ltd
ASX:DEL
|
AU |
|
S
|
Sonam Clock Ltd
NSE:SONAMCLOCK
|
IN |
|
Titan International Inc
NYSE:TWI
|
US |
|
F
|
Fujian South Highway Machinery Co Ltd
SSE:603280
|
CN |
|
V
|
VT GMP Co Ltd
KOSDAQ:018290
|
KR |
|
Wiluna Mining Corporation Ltd
ASX:WMC
|
AU |
|
G
|
Giantec Semiconductor Corp
SSE:688123
|
CN |
|
Indiabulls Real Estate Ltd
NSE:IBREALEST
|
IN |
|
N
|
Nutrien Ltd
NYSE:NTR
|
CA |
|
S
|
Siav SpA
MIL:SIAV
|
IT |
|
Takeda Pharmaceutical Co Ltd
NYSE:TAK
|
JP |
|
P
|
Pathfinder Ventures Inc
XTSX:RV
|
CA |
Multiples-Based Value
The Multiples-Based Value of one
MARKSANS
stock under the Base Case scenario is
hidden
INR.
Compared to the current market price of 156.89 INR,
Marksans Pharma Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MARKSANS Multiples-Based Value
LOCKED
Multiples Across Competitors
MARKSANS Competitors Multiples
Marksans Pharma Ltd Competitors
Marksans Pharma Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
|
Marksans Pharma Ltd
NSE:MARKSANS
|
71.1B INR | 2.5 | 19.7 | 12.8 | 15.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
837.7B USD | 12.9 | 40.6 | 27.4 | 29.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
583.9B USD | 6.2 | 21.8 | 15.1 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
228B GBP | 5.2 | 29.9 | 16.5 | 23.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
292.3B USD | 4.5 | 16 | 9.9 | 12.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
228.6B CHF | 5.3 | 21.2 | 13.1 | 16.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 10 | 7.5 | 8.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
157.9B USD | 2.5 | 20.3 | 7.8 | 10.4 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.2B USD | 2.5 | 17.1 | 7.2 | 8.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
